TABLE 1.
Characteristics of each noninvasive modality for the assessment of liver fibrosis
| Accuracy | Validation | Measurement failure |
Availability | Cost | Components | |
|---|---|---|---|---|---|---|
| Blood-based marker | ||||||
| FIB-4 | + | +++ | - | +++ | + | |
| NAFLD fibrosis score (NFS) | + | +++ | - | +++ | + | Age, AST, ALT, platelets |
| M2BPGi | ++ | + | - | +++ | ++ | Age, BMI, impaired fasting glucose/diabetes, AST, ALT, platelets, albumin |
| ELF | ++ | ++ | - | +++ | ++ | |
| PRO-C3 | ++ | + | - | +++ | ++ | Type III procollagen peptide, hyaluronic acid, tissue inhibitor of metalloproteinase-1 |
| Imaging-based marker | ||||||
| VCTE | +++ | +++ | ++ | ++ | +++ | |
| pSWE | +++ | ++ | + | +-++ | +++ | |
| 2D-SWE | +++ | + | + | +-++ | +++ | |
| MRE | ++++ | +++ | + | + | ++++ |
Notes: Plus signs indicate the score between each modality from low (+) to high (++++).
Abbreviations: 2D-SWE, two-dimensional shear wave elastography; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ELF, enhanced liver fibrosis; M2BPGi, mac-3 binding protein glycosylatlon isomer; MRE, magnetic resonance elastography; PRO-C3, N-terminal propeptide of type 3 collagen; pSWE, point shear wave elastography; VCTE, vibration-controlled transient elastography.